Sorafenib

Biological Activity

Sorafenib is a potent Raf inhibitor (IC₅₀ values are 6, 22 and 38 nM for Raf-1, wild-type BRAF and V599E BRAF mutant, respectively). Also inhibits mVEGFR-2, mVEGFR-3, mPDGFR-β, Flt-3, cKIT and VEGFR-2 (IC₅₀ values are 15, 20, 57, 58, 68 and 90 nM, respectively). Inhibits MAPK pathway in colon, pancreatic and breast cancer cells expressing mutant KRAS and mutant or wt BRAF in vitro. Exhibits antitumor activity in colon, breast and non small-cell lung cancer xenograft models. Also induces ferroptosis in hepatocellular carcinoma cells in vitro.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
   Wilhelm et al.
   Cancer Res., 2004;64:7099
2. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
   Lachaier et al.
   Anticancer Res., 2014;34:6417

Product Datasheets